AVTE Live signals | Maximize Profits with Getagraph.com

BUY 100388 min ago

@ $19.23

Issued: 13 Feb 2024 @ 09:31

Return: 15.29%

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Stats
Today's Volume	108 420
Average Volume	148 353
Market Cap	617.72M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.740 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.72
ATR14	$0.0590 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Dake Benjamin T	Sell	6 853	Stock Option (Right to Buy)
2024-04-17	Dake Benjamin T	Buy	6 853	Common Stock
2024-04-17	Dake Benjamin T	Sell	6 447	Common Stock
2024-04-17	Dake Benjamin T	Sell	338	Common Stock
2024-04-17	Dake Benjamin T	Sell	68	Common Stock

INSIDER POWER
7.26
Last 100 transactions
Buy: 446 022 \| Sell: 367 692

Volume Correlation

Long: -0.34 (neutral)

Short: -0.86 (strong negative)

Signal:(33.14) Neutral

Aerovate Therapeutics, Correlation

10 Most Positive Correlations
GRIN	0.929
SILK	0.922
DYNT	0.915
EDSA	0.912
NUWE	0.908
ANAB	0.908
AKU	0.904
UG	0.904
ATRA	0.899
FYBR	0.899

10 Most Negative Correlations
DAKT	-0.917
PESI	-0.908
DUOL	-0.907
BCOR	-0.899
DBVT	-0.896
FEXD	-0.895
BNIX	-0.894
LMB	-0.891
RCII	-0.89
CRWD	-0.888

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aerovate Therapeutics, Correlation - Currency/Commodity

0.67
( moderate )

0.83
( strong )

0.00
( neutral )

0.75
( moderate )

-0.80
( moderate negative )

Aerovate Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-96 000.00 (0.00 %)
EPS:	$-2.87

Q4	2023
Revenue:	$0
Gross Profit:	$-28 000.00 (0.00 %)
EPS:	$-0.740

Q3	2023
Revenue:	$0
Gross Profit:	$-25 000.00 (0.00 %)
EPS:	$-0.710

Q2	2023
Revenue:	$0
Gross Profit:	$-22 000.00 (0.00 %)
EPS:	$-0.760

Financial Reports:

No articles found.

Aerovate Therapeutics,

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.